Research Triangle Park, N.C., Sept. 14, 2017 — Marken announced today the large number of transportation lanes where the UPS airline and ground operations can be used in a new 'hybrid' service offering. The new service is supplemental to their existing specialty operations and will expand Marken's footprint in the global clinical trials industry.
Marken's new hybrid service enables the booking of shipments in their own proprietary Maestro operating system, managing them from origin to destination while using the UPS network in a seamlessly effective manner. The service provides more flight options and integrated tracking to and from major airports. At the same time, Marken can draw on UPS experience with temperature sensitive transportation which, when combined with Marken's experience with pharmaceuticals and clinical trials, forms a powerful combination. A new video which explains the three levels of service can be found on the company's website: www.marken.com.
Wes Wheeler, Marken's Chief Executive Officer, said, "We fully expected to take advantage of the UPS global network and announced the start of the new service earlier this year. In the past 8 months, we have delivered on our promise to offer the hybrid service and are pleased to be carrying over 10% of all shipments on a UPS aircraft. The support we are receiving from our UPS parent is very strong and is opening up many new opportunities to serve our clients. We are working every day to add lanes to the hybrid service which we believe will allow us to provide a broad range of transport solutions to our clinical clients, which will in turn allow us to continue growing in this important industry."
Marken is a wholly owned subsidiary of UPS. Marken is the only patient-centric supply chain organization 100% dedicated to the pharmaceutical and life sciences industries. Marken maintains the leading position for Direct to Patient services and biological sample shipments and offers a state-of-the-art GMP-compliant depot network and logistic hubs in 46 locations worldwide for clinical trial material storage and distribution. Marken’s more than 800 staff members manage 50,000 drug and biological shipments every month at all temperature ranges in more than 150 countries. Additional services such as biological kit production, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.